Abiopharma

Assure has been a leading provider of Intraoperative neuromonitoring ("IONM"). The Company delivered a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive surgical procedures. IONM has been well established as a standard of care and risk mitigation tool for various surgical verticals such as neurosurgery, spine, cardiovascular, orthopedic, ear, nose, and throat and other surgical procures that place the nervous system at risk. Assures mission was to provide exceptional surgical care and help make invasive surgeries safer. Our strategy focused on utilizing best of class personnel and partners to deliver outcomes that are beneficial to all stakeholders including patients, surgeons, hospitals, insurers, and stockholders. During September 2023, the Companys Board of Directors initiated a process to explore strategic alternatives for the business. As part of this review process, Assures board agreed to conduct an auction for the sale of its clinical operations. On March 11, 2024, the Company and its subsidiaries, entered into an asset purchase agreement with National Neuromonitoring Services, LLC. On March 26, 2024, Assure closed the sale transaction resulting in the disposal of most of the Companys clinical operations, equipment, and contracts. Assure currently is providing IONM services in limited markets, primarily Arizona and Montana.

Additional info from OTC:
Assure has been a leading provider of Intraoperative neuromonitoring ("IONM"). The Company delivered a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive surgical procedures. IONM has been well established as a standard of care and risk mitigation tool for various surgical verticals such as neurosurgery, spine, cardiovascular, orthopedic, ear, nose, and throat and other surgical procures that place the nervous system at risk. Assures mission was to provide exceptional surgical care and help make invasive surgeries safer. Our strategy focused on utilizing best of class personnel and partners to deliver outcomes that are beneficial to all stakeholders including patients, surgeons, hospitals, insurers, and stockholders. During September 2023, the Companys Board of Directors initiated a process to explore strategic alternatives for the business. As part of this review process, Assures board agreed to conduct an auction for the sale of its clinical operations. On March 11, 2024, the Company and its subsidiaries, entered into an asset purchase agreement with National Neuromonitoring Services, LLC. On March 26, 2024, Assure closed the sale transaction resulting in the disposal of most of the Companys clinical operations, equipment, and contracts. Assure currently is providing IONM services in limited markets, primarily Arizona and Montana.